Skip to content
Search AI Powered

Latest Stories

Blood Pressure Management: Study finds change of medication twice as great as doubling the dose

A change in medication can benefit patients on blood pressure-lowering therapies significantly more than increasing the dose of their current medication.

A recent study from Uppsala University that was published in the Journal of the American Medical Association (JAMA) demonstrates this.


In this study, four different blood pressure-lowering medications were tested out on 280 individuals over the course of a year.

"The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient's current medication. It was clear in our study that certain patients achieved lower blood pressure from one drug than from another. This effect is large enough to be clinically relevant," said Johan Sundstrom, cardiologist and Professor of Epidemiology at Uppsala University, who is the first author of the study.

Most Swedes develop high blood pressure sooner or later; more than two million Swedes have high blood pressure at the present time.

Only a fifth of them have managed to bring their blood pressure under control through drug therapy, and some studies suggest that only half of them take their blood pressure medication as intended.

Could this be because the efficacy and side-effects of the drugs differ from individual to individual?

Given the great diversity of blood pressure drugs, there is a serious risk that patients will not receive the optimal drug at the first attempt, and that this will result in poor blood pressure lowering and unnecessary side-effects.

A new study at Uppsala University investigated whether there is an optimal blood pressure drug for each individual, and therefore a potential for personalized blood pressure treatment.

The study involved 280 patients.

All these individuals tested four different blood pressure drugs, one after the other, at several different times over a total period of one year.

Researchers saw that the effect of the treatment varied widely from individual to individual and that it was clear that certain patients achieved lower blood pressure from one drug than from another. Study's findings challenge the strategy recommended in current treatment guidelines, in which four drug groups are recommended equally warmly for all patients with high blood pressure.

"If we personalize each patient's medication, we can achieve a better effect than if we choose a drug from one of these four drug groups at random. Our study shows that given the right blood pressure drug, the patient can lower their blood pressure and as a result can probably obtain better protection against future cardiovascular diseases more quickly," Sundstrom said.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less